Pembroke Management LTD Boosts Holdings in Bruker Corporation $BRKR

Pembroke Management LTD raised its stake in Bruker Corporation (NASDAQ:BRKR) by 61.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 400,893 shares of the medical research company’s stock after acquiring an additional 153,081 shares during the quarter. Bruker makes up 2.0% of Pembroke Management LTD’s holdings, making the stock its 22nd biggest position. Pembroke Management LTD’s holdings in Bruker were worth $16,517,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State of Michigan Retirement System increased its stake in shares of Bruker by 1.1% during the 1st quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company’s stock worth $1,106,000 after purchasing an additional 300 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Bruker by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the medical research company’s stock valued at $1,294,000 after purchasing an additional 300 shares during the last quarter. Parallel Advisors LLC grew its holdings in Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 347 shares during the period. UMB Bank n.a. increased its position in Bruker by 26.3% in the second quarter. UMB Bank n.a. now owns 1,673 shares of the medical research company’s stock worth $69,000 after buying an additional 348 shares during the last quarter. Finally, Allworth Financial LP increased its position in Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after buying an additional 364 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 27.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

BRKR has been the topic of a number of recent research reports. Barclays upped their price target on Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Citigroup cut their target price on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research report on Monday, August 4th. UBS Group boosted their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $48.30.

Bruker Price Performance

BRKR stock opened at $40.78 on Tuesday. The firm has a 50 day moving average of $35.15 and a 200-day moving average of $37.09. The firm has a market capitalization of $6.20 billion, a P/E ratio of 78.42, a price-to-earnings-growth ratio of 5.31 and a beta of 1.26. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $64.64. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. During the same period in the prior year, the company posted $0.60 EPS. The business’s revenue for the quarter was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, sell-side analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is currently -125.00%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.